6 assets in Psoriatic Arthritis

Therapeutic assets addressing Psoriatic Arthritis, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Tirzepatide Psoriatic Arthritis	JULIO GRANADOS MONTIEL	P4	BBB (74)
Ixekizumab Psoriatic Arthritis	NHS Greater Glasgow and Clyde	P3	BB (64)
Cabozantinib Psoriatic Arthritis	National Cancer Institute (NCI)	P1	CC (43)
Ipilimumab Psoriatic Arthritis	National Cancer Institute (NCI)	P1	CC (43)
Nivolumab Psoriatic Arthritis	National Cancer Institute (NCI)	P1	CC (43)